Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT04350255
Recruiting Not applicable

A Register Based Prospective Study During Implementation of a New Cup

NCT04350255 · tracked via the Priya Life Science Sweden tracker
Sponsor
Sahlgrenska University Hospital
Phase
Not applicable
Started
2020-08-01
Last updated
2022-10-04

Condition(s) studied

Prospective

Investigational drug(s) / intervention(s)

Total hip arthroplastyTotal hip arthroplasty

Total hip arthroplasty: Total hip arthroplasty with a Trident II hemispherical cup

Total hip arthroplasty: Total hip arthroplasty with a Trident II Tritanium cup

Study summary

In a prospective register-based study, we aim to evaluate the implant survival, clinical outcomes and X-ray findings by following a cohort of patients operated with the Trident II cup.

Eligibility

Sex
ALL
Min age
30 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Primary hip replacement * Eligible for uncemented fixation of the acetabular component * Suitable for one of the stem designs from Stryker Orthopaedics * Accepts follow-up according to the study protocol Exclusion Criteria: * Difficulties to understand written information due to language problems or other reasons * Use of augments needed * Acute hip fracture * Tumor in the hip joint

Primary outcome measure(s)

  • Implant survival at 3 years — 3 years
    Kaplan Meier survival data, cup revision and risk of revision used as endpoints

Trial sites (1)

FacilityCityRegionStatus
Department of Orthopaedics Mölndal Västra Götaland County Recruiting

More Sahlgrenska University Hospital trials in Sweden

Venous Resection in Patients Undergoing Pancreatic Surgery Starting soon
Preventive Physical Activity Intervention in Head and Neck Cancer Recruiting
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients Recruiting
CBT Treatment for Internet Gaming Disorder Starting soon
Patient-reported Pain and Symptom Relief During Three Months After Surgery for Benign Prostatic Hyperplasia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04350255 on ClinicalTrials.gov ↗ ← All trials in Sweden